Prostate Cancer Update

Research To Practice

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing urologists and radiation oncologists ongoing access to the perspectives and opinions of national and international prostate cancer research leaders.

  1. -5 j

    Urothelial Bladder Cancer — Year in Review Series on Relevant New Datasets and Advances

    Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics: Introduction: Life After Radical Cystectomy (0:00)Muscle-Invasive Bladder Cancer — Prof Powles (9:15)Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49) CME information and select publications

    58 min

  2. 23 juin

    Prostate Cancer — Fifth Annual National General Medical Oncology Summit

    Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics: Introduction (0:00)Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41)Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16) CME information and select publications

    50 min

  3. 17 juin

    Urothelial Bladder Cancer — Fifth Annual National General Medical Oncology Summit

    Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics: Introduction (0:00)Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41) CME information and select publications

    49 min

  4. 16 juin

    Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting

    Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics: Introduction (0:00)Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26) CME information and select publications

    1 h 58 min

  5. 12 juin

    Localized Renal Cell Carcinoma — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting

    Dr Thomas Hutson from the Sarah Cannon Research Institute in Abilene, Texas, Dr Eric A Singer from The Ohio State University Comprehensive Cancer Center in Columbus and Dr Ulka Vaishampayan from the University of Michigan Health Rogel Cancer Center in Ann Arbor discuss recent data surrounding the management of localized renal cell carcinoma and share their perspectives on the clinical application. CME information and select publications

    1 h 29 min

  6. 5 juin

    Genitourinary Cancers — 5-Minute Journal Club Issue 2 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

    Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer. CME information and select publications

    23 min

  7. 26 mai

    Genitourinary Cancers — 5-Minute Journal Club Issue 1 with Professor Thomas Powles: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

    Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer. CME information and select publications here.

    30 min

  8. 15 mai

    PARP Inhibitors for Patients with Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer — An Interview with Dr Wassim Abida

    Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer. CME information and select publications here.

    52 min
Tout afficher (66)

À propos

Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing urologists and radiation oncologists ongoing access to the perspectives and opinions of national and international prostate cancer research leaders.

Informations

  • Chaîne
    Research To Practice
  • Création
    Dr. Neil Love
  • Années d’activité
    2006 - 2026
  • Épisodes
    66
  • Classification
    Tous publics
  • Copyright
    © Copyright 2025 Research To Practice. All Rights Reserved
  • Site web de l’émission
    Prostate Cancer Update
  • Fournisseur

Plus de contenus par Research To Practice

Vous aimeriez peut‑être aussi